EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study

Clara Ureña-Paniego, Trinidad Montero-Vílchez iD, Raquel Sanabria-de-la-Torre iD, Alberto Soto-Moreno, Alejandro Molina-Leyva iD, Salvador Arias-Santiago iD

International Journal of Environmental Research and Public Health · 2023

DOI: 10.3390/ijerph20031918 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Clara Ureña-Paniego und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Virgen de las Nieves University Hospital, 18012 Granada, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Erectile Dysfunction, Eczema. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting as xerosis, eczema and intense pruritus. These symptoms negatively impact patients’ quality of life. However, the effect of AD on sexual function and sleep quality and how treatment with dupilumab could modify them have not been explored in depth. The aim of this study is to assess the effects of dupilumab on sexual and sleep quality in patients with AD. For that purpose, an observational prospective study was designed. Patients were evaluated at baseline and after 16 weeks of dupilumab treatment. Disease severity was assessed by Eczema Area and Severity (EASI) and SCORing Atopic Dermatitis index (SCORAD). Sexual function was evaluated using validated questionnaires, for men via the International Index of Erectile Dysfunction 5 (IIEF-5) and for women via the Female Sexual Function Index (FSFI). Sleep impairment was recorded through Pittsburgh Sleep Quality Index (PSQI). Thirty-two patients, with a mean age of 30.53 ± 14.48 years old, were included. Regarding sex, 59.8% (20) were female. Most patients had a severe disease reflected in a mean basal EASI of 23.24 ± 6.74 and a SCORAD of 54.07 ± 13.89. Clinical scores improved after dupilumab treatment. At baseline, 47.37% women presented sexual dysfunction and 66.67% men had erectile dysfunction. FSFI improved from 23.51 to 27.93 points (p = 0.008) after dupilumab. Desire, arousal, satisfaction and pain were the components with great improvement. Women with a great improvement in FSFI showed greater clinical results and increased quality of life. At first, 96.9% (31/32) of participants presented with poor sleep quality. After treatment with dupilumab, sleep quality was enhanced and PSQI scores decreased from 12.8 points at baseline to 7.73 points (p < 0.001). In conclusion, dupilumab is associated with reduced sexual dysfunction, mainly in women, and sleep quality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicErectile DysfunctionEczemaMaleHumansFemaleAdolescentYoung AdultAdultMiddle AgedProspective StudiesSleep QualityQuality of LifeSeverity of Illness IndexTreatment OutcomeDouble-Blind MethodAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

atopic dermatitisdupilumabsexual healthsleep quality

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Virgen de las Nieves University Hospital, 18012 Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.
  • Cell Production and Tissue Engineering Unit, Virgen de las Nieves University Hospital, Andalusian Network, 18014 Granada, Spain.
  • Department of Dermatology, Faculty of Medicine, University of Granada, 18071 Granada, Spain.

ORCID-Profile: Trinidad Montero-Vílchez, Raquel Sanabria-de-la-Torre, Alejandro Molina-Leyva, Salvador Arias-Santiago

Zitieren

APA

Ureña-Paniego, C., Montero-Vílchez, T., Sanabria-de-la-Torre, R., Soto-Moreno, A., Molina-Leyva, A., & Arias-Santiago, S. (2023). Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20031918

Vancouver

Ureña-Paniego C, Montero-Vílchez T, Sanabria-de-la-Torre R, Soto-Moreno A, Molina-Leyva A, Arias-Santiago S. Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20031918

BibTeX
@article{UreaPaniego2023,
  author = {Ureña-Paniego, Clara and Montero-Vílchez, Trinidad and Sanabria-de-la-Torre, Raquel and Soto-Moreno, Alberto and Molina-Leyva, Alejandro and Arias-Santiago, Salvador},
  title = {Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study},
  journal = {International Journal of Environmental Research and Public Health},
  year = {2023},
  doi = {10.3390/ijerph20031918}
}
Kostenlos starten →